8-K: AgeX Therapeutics Implements 1-for-35.17 Reverse Stock Split and Approves Merger Proposals

AgeX Therapeutics has completed a 1-for-35.17 reverse stock split and secured stockholder approval for key merger proposals with Serina Therapeutics.

Summary

• AgeX Therapeutics' stockholders approved a reverse stock split at a ratio of 1-for-35.17.
• The reverse stock split became effective on March 14, 2024, at 10:00 a.m. Eastern Time.
• Each 35.17 shares of AgeX common stock were combined into one new share.
• No fractional shares were issued; instead, stockholders received cash based on the closing price of AgeX common stock on the last trading day before the split.
• AgeX common stock began trading on a split-adjusted basis on March 15, 2024, with a new CUSIP number.
• Stockholders also approved proposals related to the merger with Serina Therapeutics, including the issuance of shares and warrants.
• The merger is expected to be completed on March 26, 2024.
• The combined company will be renamed Serina Therapeutics, Inc., and will trade under the ticker symbol SER starting March 27, 2024.

Sentiment

Score: 6

Explanation: The document is neutral to slightly positive. The reverse stock split is a necessary step for the merger, and the merger itself is a positive strategic move. However, there are risks associated with the merger and the combined company's future operations.

Positives

• The reverse stock split was successfully implemented, which may help the company meet listing requirements.
• Stockholder approval for the merger with Serina Therapeutics indicates support for the strategic direction of the company.
• The merger is expected to be completed soon, which will create a new entity with a new ticker symbol.

Negatives

• The reverse stock split reduces the number of outstanding shares, which can be perceived negatively by some investors.
• The merger will result in a change of control and a new company name, which may cause uncertainty.

Risks

• The merger is subject to certain conditions that may not be satisfied.
• The combined company may face challenges in integrating operations and realizing the expected benefits of the merger.
• There are risks associated with conducting and financing Serina's research and development programs.
• The combined company may not be able to obtain necessary regulatory approvals or successfully commercialize products.
• The combined company's cash balance may be lower than expected, and they may need additional financing.
• The company may face risks related to intellectual property protection, product liability, and competition.

Future Outlook

The merger with Serina Therapeutics is expected to be completed on March 26, 2024, with the combined company trading under the ticker symbol SER starting March 27, 2024. The company anticipates challenges related to integrating operations, research and development, and commercialization.

Management Comments

• The board of directors of AgeX approved the Reverse Stock Split at a ratio of 1-for-35.17.
• The board of directors of the corporation is authorized to fix by resolution or resolutions the designations and the powers, preferences and rights, and the qualifications, limitations or restrictions and the number of shares of any series of Preferred Stock and to determine or alter the rights, preferences, privileges, and restrictions granted to or imposed upon the Preferred Stock as a class, or upon any wholly unissued series of Preferred Stock.

Industry Context

Reverse stock splits are often used by companies to increase their stock price and meet listing requirements. The merger with Serina Therapeutics is a strategic move to combine resources and expertise in the biotechnology sector.

Comparison to Industry Standards

• Reverse stock splits are a common mechanism for companies facing delisting from major exchanges, such as the NYSE American, and AgeX's 1-for-35.17 split is within the typical range for such actions.
• Mergers in the biotech industry are frequent, with companies like Celgene (acquired by Bristol Myers Squibb) and Alexion (acquired by AstraZeneca) demonstrating the potential for value creation through strategic combinations. AgeX's merger with Serina is similar in that it aims to combine complementary technologies and pipelines.
• The voting results for the merger proposals are generally in line with expectations for such transactions, with a majority of shareholders approving the key resolutions. This is similar to other biotech mergers where shareholder support is crucial for deal completion.

Stakeholder Impact

• Shareholders will experience a reduction in the number of shares they own due to the reverse stock split.
• Shareholders will receive cash for any fractional shares resulting from the reverse stock split.
• Employees may experience changes due to the merger and integration of the two companies.
• Customers and suppliers may see changes in the company's operations and offerings.

Next Steps

• The merger with Serina Therapeutics is expected to be completed on March 26, 2024.
• The combined company will begin trading under the ticker symbol SER on March 27, 2024.
• The company will need to integrate operations and execute its business plan.

Key Dates

Keywords

reverse stock split, merger, Serina Therapeutics, stockholder approval, NYSE American, corporate action, common stock, ticker symbol, CUSIP number